It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...
Verdiva launched with $411 million. Indian drugmaker Anthem Biosciences filed for an IPO worth $397 million. Tenvie Therapeutics emerged with $200 million. Maze Therapeutics files for $115 million ...
Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target at $8.00. Discover outperforming stocks and invest ...
Tenvie Therapeutics Inc. is getting a set of small-molecule drugs — specifically, ones aimed at tamping down inflammation, rescuing metabolic dysfunction and restoring lysosomal function ...
The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases. BioWorld ...
Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tenvie Therapeutics launched today with a commitment to transform the treatment of neurological diseases. The company combines a deep and diverse portfolio of small ...
A new startup has emerged with $200 million and access to multiple preclinical drug candidates from neuroscience drugmaker Denali Therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback